KW-6500 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease4

6. Parkinson disease


Clinical trials : 2,307 Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01063621
(ClinicalTrials.gov)
January 20104/2/2010Extended Long-Term Safety Study of KW-6500Phase 3 Study of KW-6500 (Safety Study for Extended Long-Term Self-Injection at Home in Patients With Parkinson's Disease)Parkinson's DiseaseDrug: KW-6500Kyowa Hakko Kirin Co., LtdNULLCompleted20 YearsN/AAll27Phase 3Japan
2NCT01058291
(ClinicalTrials.gov)
January 201027/1/2010Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500Phase 3 Study of KW-6500 (Placebo-Controlled Double-Blind Crossover Comparative Study in Patients With Parkinson's Disease)Parkinson's DiseaseDrug: KW-6500;Drug: KW-6500 PlaceboKyowa Hakko Kirin Co., LtdNULLCompleted20 YearsN/AAll31Phase 3Japan
3NCT00955318
(ClinicalTrials.gov)
July 20097/8/2009Long-Term Safety Study of KW-6500 in Patients With Parkinson's DiseasePhase 3 Study of KW-6500 (Safety Study for Long-Term Self-Administration at Home in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: KW-6500Kyowa Hakko Kirin Co., LtdNULLCompleted20 YearsN/AAll58Phase 3Japan
4NCT00610103
(ClinicalTrials.gov)
November 200722/1/2008Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa TherapyA Phase 2 Clinical Study of KW-6500 (Apomorphine Hydrochloride) in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: apomorphine hydrochlorideKyowa Kirin Co., Ltd.NULLCompleted20 YearsN/AAll16Phase 2Japan